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ABSTRACT
Osteogenesis imperfecta (OI) types VII, VIII and IX, caused by
recessive mutations in cartilage-associated protein (CRTAP), prolyl-3-
hydroxylase 1 (P3H1) and cyclophilin B (PPIB), respectively, are
characterized by the synthesis of overmodified collagen. The genes
encode for the components of the endoplasmic reticulum (ER) complex
responsible for the 3-hydroxylation of specific proline residues in type I
collagen. Our study dissects the effects of mutations in the proteins of
the complex on cellular homeostasis, using primary fibroblasts from
seven recessive OI patients. In all cell lines, the intracellular retention of
overmodified type I collagen molecules causes ER enlargement
associated with the presence of protein aggregates, activation of the
PERK branch of the unfolded protein response and apoptotic death.
The administration of 4-phenylbutyrate (4-PBA) alleviates cellular
stress by restoring ER cisternae size, and normalizing the
phosphorylated PERK (p-PERK):PERK ratio and the expression of
apoptotic marker. The drug also has a stimulatory effect on autophagy.
We proved that the rescue of cellular homeostasis following 4-PBA
treatment is associated with its chaperone activity, since it increases
protein secretion, restoring ER proteostasis and reducing PERK
activation and cell survival also in the presence of pharmacological
inhibition of autophagy. Our results provide a novel insight into the
mechanism of 4-PBA action and demonstrate that intracellular stress in
recessive OI can be alleviated by 4-PBA therapy, similarly to what we
recently reported for dominant OI, thus allowing a common target for OI
forms characterized by overmodified collagen.
This article has anassociated First Person interviewwith the first author
of the paper.
KEY WORDS: Osteogenesis imperfecta, Endoplasmic
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INTRODUCTION
Osteogenesis imperfecta (OI) is a collagen-related heritable
disorder affecting several connective tissues, but is mainly
characterized by skeletal deformity and bone fragility (Marini
et al., 2017). Together with the dominant forms caused by
mutations in type I collagen and representing over 85% of OI
cases, recessive and X-linked OI have been described since
2006. These forms are characterized by defects in proteins involved
in collagen type I folding, post-translational modifications,
intracellular trafficking, extracellular processing or osteoblasts
maturation (Forlino and Marini, 2016; Lindert et al., 2016).
Synthesis of type I collagen includes a complex intracellular
and extracellular series of events preceding mature collagen fibril
formation and involves several molecular players. Briefly, two proα1
and one proα2 chains are synthesized in the endoplasmic reticulum
(ER) and linked in a trimeric molecule thanks to specific C-terminal
recognition sequences and covalent disulfide bridges occurring
in close proximity to the ER membrane. During their translation
and before triple-helical folding, the α-chains undergo various post-
translational modification events, including hydroxylation of proline
inC-4 andC-3 and of lysine residues (Ishikawa andBächinger, 2013).
Proline-4 hydroxylation, catalyzed by prolyl-4-hydroxylase B (P4HB),
affects almost all the proline residues placed in the Y position of the
collagen triplet unit (Gly-X-Y). 4(R)-hydroxy-L-proline (4-Hyp)
residues are fundamental for helix stability by favoring water-bridged
intramolecular hydrogen bonding. The hydroxylation of triple helical
and telopeptide lysine residues, performed by lysyl hydroxylase 1
and lysyl hydroxylase 2, respectively, provides the substrates for
successive intracellular glycosylation and extracellular covalent
crosslink formation. The role of 3(S)-hydroxy-L-proline (3-Hyp)
instead is still poorly defined (Hudson and Eyre, 2013; Pokidysheva
et al., 2014). Very few proline residues in collagen type I are
3-hydroxylated, likely excluding their role in collagen stability (Marini
et al., 2007). In α1(I), only Pro986 is always present as 3-Hyp and this
post-translational modification is performed by prolyl-3-hydroxylase
1 (P3H1) that is associated in a 1:1:1 ratio with cartilage-associated
protein (CRTAP) and cyclophilin B (CyPB) to form a complex active
in the ER (Ishikawa et al., 2009). The relevance of 3-Hyp in collagen
folding as well as in proper fibril formation was proposed following
the identification of three recessive OI forms characterized by the lack
of α1(I)Pro986 C-3 hydroxylation and caused by mutations in one
of the three genes encoding the proteins of the ER complex (Marini
et al., 2007). Defects in CRTAP, the helper protein of the complex,
are responsible forOI typeVII (OMIM#610682), and patients showa
moderate to lethal phenotype with growth deficiency, rhizomelia,
severe osteoporosis and neonatal fractures (Morello et al., 2006).
OI type VIII (OMIM # 610915) is the consequence of mutations in
P3H1, the protein of the complex that catalyzes α1(I)Pro986 C-3
hydroxylation. OI type VIII patients usually show a severe to lethal
phenotype with the symptoms overlapping those of type VII (CabralReceived 8 January 2019; Accepted 20 May 2019
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et al., 2007). Importantly, CRTAP and P3H1 are mutually stabilizing
in the ER (Chang et al., 2010).
Mutations in PPIB are responsible for OI type IX (OMIM #
259440). PPIB encodes for CyPB, the peptidyl-prolyl cis-trans
isomerase that catalyzes the isomerization of the peptide bonds
involving proline residues, the rate-limiting step reaction in collagen
folding. The phenotype of OI type IX patients ranges frommoderate
to lethal, partially overlapping OI type VII and VIII forms, but
without rhizomelia (Barnes et al., 2010; van Dijk et al., 2009).
The absence of CRTAP, P3H1 and CyPB, associated with
complete lack or reduced α1(I)3-Hyp986, delays collagen type I
folding, causing overmodification of the helical region and decreased
collagen secretion at least in OI dermal fibroblasts (Marini et al.,
2007). A still open question to understand the molecular basis of
these OI recessive forms is whether the OI phenotype is caused by the
absence of 3-Hyp in the bone matrix or by a defect in intracellular
collagen folding and secretion, or a combination of both.
Interestingly, in a knock-in mouse in which the P3H1 catalytic site
was inactivated, but the enzyme was still able to complex with
CRTAP, a mild bone phenotype was present (Homan et al., 2014).
The overmodified collagen molecules secreted in the extracellular
matrix (ECM) in OI type VII, VIII and IX assemble in irregular
fibrils, which impair proper mineralization, affecting bone properties,
but their intracellular effects are still unknown (Forlino et al., 2011).
Interestingly, using a functional proteomic approach on lysates
obtained from primary fibroblasts of patients with mutations in
CRTAP, P3H1 or PPIB, we demonstrated an altered cytoskeleton and
altered nucleoskeletal assembly, pointing to an impairment of the
intracellular compartment (Gagliardi et al., 2017).
No effective therapy is available for any of the OI forms, and
bisphosphonates, the most commonly used drugs, are anti-catabolic
molecules that impair osteoclast activity and bone remodeling,
improving bone mineral density, but without positive effects on bone
properties (Besio and Forlino, 2015). Thus, the search for new and,
likely, common pharmacological targets for multiple OI forms is an
urgent patient need. We used seven primary fibroblast lines obtained
from recessive OI type VII, VIII and IX patients to evaluate how cells
react to the presence of overmodified collagen because of mutations
in the components of the collagen prolyl-3-hydroxylase complex.
We demonstrated that mutant collagen accumulates in the ER,
causing unfolded protein response (UPR) activation and apoptotic
death. We proved that the administration of the chemical chaperone
4-phenylbutyrate (4-PBA) ameliorates cellular homeostasis by
mainly favoring protein secretion.
RESULTS
Primary fibroblasts from seven previously described (PPIB)
recessive OI patients with mutations in the components of the
Table 1. List of the human primary fibroblast cells used in the study
Patient Gene Protein Gene mutation Protein mutation
OI
type Clinical phenotype Reference
CRTAP-1 CRTAP CRTAP c.118_133del16insTACCC/
c.118_133del16insTACCC
Glu40Tyrfs*117 VII Short stature, long-bone fractures
and deformities, vertebral
deformities, rhizomelia, grayish
sclerae
Valli et al., 2012
CRTAP-2 CRTAP CRTAP c.-1677_471+1592del/c.-
1677_471+1592del
Not reported VII Short stature, long-bone fractures
and deformities, vertebral
deformities, scoliosis, pectus
carinatum, wormian bone,
osteoporosis, joint
hypermobility, rhizomelia, faint
blue sclerae at birth
Caparros-Martin
et al., 2013
CRTAP-3 CRTAP CRTAP c.804_809delAGAAGT/
c.804_809delAGAAGT
Glu269_Val270del VII Short stature, long-bone fractures
and deformities, rib fractures,
vertebral deformities,
compression and fractures,
scoliosis, osteopenia, no
rhizomelia, grayish sclerae
Amor et al., 2011
P3H1-1 P3H1 P3H1 c.2148delC Glu719Asnfs*747 VIII Short stature, long-bone fractures
and deformities, vertebral
deformities, osteopenia
Our unpublished
data
P3H1-2 P3H1 P3H1 c.1223+2T>G/c.1223+2T>G Not reported VIII Short stature, long-bone fractures
and deformities, pectus
carinatum, wormian bones,
vertebral deformities, scoliosis,
osteoporosis, joint hypermobility,
faint blue sclerae at birth
Caparros-Martin
et al., 2013
P3H1-3 P3H1 P3H1 c.765C>A/c.2055+18G>A Tyr255Ter
splice site
VIII 22-week-old fetus: severe skeletal
dysplasia characterized by
short, bowed and deformed long
bones
Our unpublished
data
CyPB PPIB CyPB c.497A>C/c.497A>C His166Pro IX Short stature, long-bone fractures
and deformities, pectus
carinatum, flaring of ribs, wormian
bones, vertebral deformities,
kyphoscoliosis, osteoporosis, joint
hypermobility, dusky color of the
sclerae
Caparros-Martin
et al., 2013
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3-hydroxylation complex were selected for the study. Three patients
carry mutations in CRTAP (CRTAP-1, CRTAP-2 and CRTAP-3),
three in P3H1 (P3H1-1, P3H1-2 and P3H1-3) and one in PPIB
(CyPB) (Table 1).
In CRTAP-1, in which the mutation is predicted to cause a
frameshift resulting in a premature stop codon, and in CRTAP-2, in
which a large genomic deletion including exon 1 was described,
a strongly reduced (0.036±0.019) and no CRTAP expression,
respectively, were detected by quantitative real-time PCR (qPCR),
suggesting the activation of nonsense-mediated decay (Fig. 1A).
Similarly, a reduced P3H1 expression (0.146±0.03) was present in
P3H1-2 cells carrying an intronic mutation in intron 7, predicted to
impair normal splicing. Indeed, no exon 6-8 amplicon was detected
by reverse-transcription PCR (RT-PCR), but a band with higher
molecular weight, compatible with the retention of the intronic
sequence, was detected (Fig. 1B).
A reduction of about 50% of P3H1 transcript was demonstrated in
P3H1-3, a compound heterozygous for an allele carrying a missense
mutation and a second allele predicted to impair the translation
of the KDEL ER-retention signal. The defect in the P3H1-1 patient,
the only one not molecularly characterized yet, was identified as a
single-nucleotide deletion (c.2148delC) in P3H1 exon 15. The
mutation causes a frameshift and the introduction of a premature stop
codon at position 747 (Glu719Asnfs*747). Only a slightly reduced
P3H1 expression (0.78±0.03) was detected (Fig. 1A). As expected,
no impairment of CRTAP expression was found in CRTAP-3,
carrying the homozygous deletion of 6 nucleotides (nt) responsible
for the in frame removal of amino acids Glu269 and Val270, or in
CyPB, carrying a homozygous single base-pair substitution
generating the His166Pro in CyPB (Fig. 1A).
At the protein level, all cells from patients carrying mutations in
CRTAP showed the absence of both CRTAP and P3H1 expression
and, similarly, patients with mutations in P3H1 showed no P3H1 and
CRTAP expression, as expected given the mutual protection of these
proteins in the complex (Chang et al., 2010). By contrast, the level of
the third component, CyPB, was not affected (Fig. 1C). No CyPB
expression was detectable in PPIB mutant cells despite normal
transcript level, but the level of CRTAP and P3H1 proteins were
within the normal range (CRTAP 1.00±0.19; P3H1 1.00±0.28).
Mutations in the components of the prolyl 3-hydroxylation
complex impair collagen structure and cell survival
The impairment of the 3-hydroxylation complex is known to affect
type I collagen folding, causing its increased hydroxylation
and glycosylation (Forlino and Marini, 2016). In all analyzed OI
cells, the presence of collagen overmodification was confirmed by
electrophoretic analysis of 3H-labeled type I collagen. Steady-state
collagen gels revealed the typical broadening of the α(I) bands in
both cell-layer and medium fractions (Fig. 2A). Furthermore, an
increase of collagen retention was detected in mutant cells
Fig. 1. Loss of mutant CRTAP, P3H1 and CyPB in
OI patient fibroblasts. (A) Quantitation of CRTAP, P3H1
and PPIB expression evaluated by qPCR. Mutations in
CRTAP, P3H1 and PPIB caused a close to complete
absence of the mutated transcripts in CRTAP-1, CRTAP-
2 and P3H1-2 patients, and a reduced mRNA level in
P3H1-1 and P3H1-3. *P<0.05. WT values are
represented as black dots; CRTAP as gray dots; P3H1 as
white dots; CyPB as dark gray dots. (B) Amplification of
the exon 6-exon 8 region ofP3H1 transcript generated the
expected 217 bp amplicon in control cells (WT), whereas,
in the P3H1-2 patient, the presence of a higher molecular
weight (∼400 bp) band compatible with intronic
retention was detected. C-, RT-PCR negative control.
(C) Representative western blot to evaluate the
expression of CRTAP, P3H1 and CyPB in control (WT)
and mutant cell lysate fractions (CRTAP-1, CRTAP-2,
CRTAP-3, P3H1-1, P3H1-2, P3H1-3, CyPB). Loss of the
mutated protein in patient’s cells was demonstrated.
Patients with mutations in CRTAP showed also no P3H1
expression and patients with mutations in P3H1 showed
no CRTAP expression, as a consequence of their
mutual protection in the complex.
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compared to controls, and kinetic analysis showed a decrease in
collagen secretion (Fig. 2B and Fig. S1).
Electron microscopy imaging revealed the presence of large
vacuoles, resembling autophagosome vesicles since double
membranes were occasionally detectable, and the ER cisternae
were clearly enlarged compared to control cells. The ER looked
normal in P3H1-2 cells (Fig. 5B).
Apoptosis occurrence was demonstrated in all OI mutant cells by
the increased level of cleaved caspase 3 (Fig. 3A) and confirmed by
fluorescence activated cell sorting (FACS) upon annexin V/Dead-
positive cell labeling. Indeed, an higher percentage of apoptotic
cells compared to controls (4.31±0.78%) was detected by FACS
in CRTAP-2, CRTAP-3, P3H1-2, P3H1-3 and CyPB fibroblasts
(49.00±5.2%, 35.74±3.57%, 22.86±2.83%, 53.93±2.17 and
20.42±1.11%, respectively) (Fig. 3B and Fig. S2).
UPR isactivated in fibroblasts frompatientswith recessiveOI
Given the intracellular presence of overmodified collagen molecules
in the recessive patients’ fibroblasts, we investigated the expression of
the chaperones binding immunoglobulin protein (BIP) and protein
disulfide isomerase (PDI) and the activation of the three branches of
the UPR: the eukaryotic translation initiation factor 2 alpha kinase 3
(PERK) branch, the inositol-requiring enzyme 1α (IRE1 α) branch
and the activating transcription factor 6 (ATF6) branch.
Four out of seven cell lines showed an increased level of both BIP,
the best-characterized activator of the UPR sensors, and PDI, which
catalyzes the formation and isomerization of disulfide bonds
necessary for protein native state and which is known to interact
with single collagen α chains (Fig. 3C) (Wilson et al., 1998).
The phosphorylated PERK (p-PERK):PERK ratio was
significantly increased in all mutant cells with the exception of
P3H1-2, in which a trend was detectable. Consistently, in these cell
lines the expression of activating transcription factor 4 (ATF4), the
effector of p-PERK, was also increased (Fig. 3C), confirming the
activation of the UPR branch. No activation of the ATF6 and IRE1α
branches was identified since no difference in cleaved ATF6 was
detected and the IRE1α-mediated splicing of XBP1 in mutants was
comparable to controls (Fig. 3D).
Based on these data, we demonstrated that mutations in the prolyl-
3-hydroxylation complex, causing the synthesis of overmodified
collagen, lead to the disruption of ER homeostasis and consequent
activation of the PERK branch of the UPR in OI fibroblasts.
RecessiveOI fibroblasts react to cellular stress byactivating
autophagy
Given the presence and/or intracellular accumulation of overmodified
collagen molecules and with autophagy being the first cell response
to constitutive dysfunctional cellular components, its activation was
investigated, evaluating the expression of the terminal autophagic
marker, the microtubule-associated protein 1A/1B-light chain 3
(LC3-II). The expression of LC3-II was upregulated in all cases
except in patient P3H1-2 (Fig. 4A). Following chloroquine treatment,
the expression of LC3-II was increased compared to wild type (WT)
in CRTAP-2, CRTAP-3, P3H1-2 and CyPB cells, indicating a
general accumulation of LC3-II due to the block in autophagic flux
(Fig. 4B). The quantitation of LC3 immunofluorescence in OI
fibroblasts treated with chloroquine was performed to validate the
activation of the autophagic pathway by an independent assay. As
expected, the LC3 signal was significantly increased compared to
controls in CRTAP-2, CRTAP-3, P3H1-2 and CyPB cells, in
agreement with the western blot data (Fig. 4C).
4-PBA ameliorates recessive OI fibroblasts homeostasis
To alleviate cellular stress due to intracellular retention of
overmodified collagen molecules, patient fibroblasts and control
cells were treated with 4-PBA, a well-known chemical chaperone,
FDA-approved as an ammonia scavenger for urea cycle disorders
(Matoori and Leroux, 2015). The effect of the drug was evaluated
following the activation of the PERK branch of the UPR and the
activation of caspase 3, as a signature for apoptosis, by western
blotting. Their levels were compared in control and OI treated versus
untreated cells and in treated OI cells versus untreated controls. None
of the selected markers was significantly changed inWT after 4-PBA
Fig. 2. Mutations in the collagen prolyl-3-hydroxylation complex lead
to collagen overmodifications and collagen intracellular retention.
(A) Representative SDS-urea-PAGE fluorographies of 3H-labeled collagen
extracted from the cell layer and medium of control (WT) and patient
(CRTAP-1, CRTAP-2, CRTAP-3, P3H1-1, P3H1-2, P3H1-3, CyPB) fibroblasts.
In mutant samples, broader and slower α(I) bands demonstrated the
overglycosylation of type I collagen. (B) The percentage of intracellular
collagen retention was evaluated as a ratio between the CPM in the cell
layer and in medium plus cell layer. Collagen molecules in mutant cells
were more intracellularly retained compared to WT. *P<0.05. WT values are
represented as black dots; CRTAP as gray dots; P3H1 as white dots; CyPB as
dark gray dots.
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administration (data not shown). Interestingly, following the
treatment, p-PERK:PERK and cleaved caspase 3 levels were
decreased to or even less than control values in all cases (Fig. 5A).
The positive effect of the drug on recessive OI cellular homeostasis
was further confirmed by the reduction of ER cisternae size, as
evaluated by transmission electron microscopy (Fig. 5B). No rescue
of CRTAP and CyPB was instead detected after the treatment in the
patients with normal transcript level, indicating that the 4-PBA effect
is not due to rescue of folding of the mutant proteins (Fig. 5C).
4-PBA chaperone function rescues recessive OI cell
homeostasis
In order to determine the mechanism of action of 4-PBA, we
investigated in our system the effect of the drug on collagen secretion
and on general protein secretion. Collagen secretion was unaffected
by the treatment, as were collagen post-translational modifications
(data not shown). However, protein labeling with 35S-L-methionine
and 35S-L-cysteine revealed an increased total protein secretion upon
4-PBA administration in all the cells tested in which it was severely
affected in the basal condition, namely CRTAP-1, P3H1-1, P3H1-2
and P3H1-3 (Fig. 6A), indicating its chaperone activity.
Interestingly, an increased LC3-II level in all mutant cells treated
with 4-PBA was detected, clearly supporting a 4-PBA stimulatory
effect on autophagy in OI recessive cells (Fig. 6B). In order to
determine whether the rescue of the cellular homeostasis following
4-PBA treatment was due to its chaperone function or to its
autophagy-stimulating ability, ER proteostasis, PERK activation
and cell survival were monitored in the absence or presence of
chloroquine, a pharmacological inhibitor of autophagy. Thioflavin
T (ThT), a small molecule that exhibits increased fluorescencewhen
it binds to protein aggregates, was used to quantify ER proteostasis
(Beriault and Werstuck, 2013). Enhanced ThT fluorescence was
detectable in mutant cells compared to control, indicating the
accumulation of intracellular misfolded material (Fig. 7A). 4-PBA
treatment significantly reduced the ThT fluorescence, proving the
reduction of protein accumulation (Fig. 7A). Importantly, this effect
of 4-PBA was evident also when inhibiting autophagy with
chloroquine (Fig. 7A). Furthermore, the p-PERK:PERK ratio and
Fig. 3. Activation of apoptosis and the UPR in recessive OI patient fibroblasts. (A) Representative western blot (left) to evaluate the expression of cleaved
caspase 3 (CASP3), a terminal marker for apoptosis and the dot plot of the quantitation analysis (right). β-actin was used for normalization. (B) Quantitative
analysis of the fraction of apoptotic events in the cell lines following FACS analysis upon cells staining with annexin V (FITC) and propidium iodide (PI). Apoptosis is
activated in all tested OI patients’ cells. (C) Representative western blots (left) and dot plots of the quantitative analysis (right and bottom) of the collagen chaperone
PDI and of proteins involved in the UPR (BIP, PERK, p-PERK, ATF4, ATF6) in control (WT) cells and in cells with mutations in CRTAP, P3H1 or CyPB. The PERK
branch of the UPRwas upregulated in all patients’ fibroblasts with the exception of patient P3H1-2. β-actin was used for normalization. WT values are represented as
black dots; CRTAPas gray dots; P3H1 as white dots; CyPB as dark gray dots. *P<0.05. (D) RT-PCRamplification ofXBP1mRNA from control (WT) and patient cells.
The spliced XBP1-1s form of XBP1 transcript (XBP-1u) is not detectable in patient cells. Fibroblasts treated with thapsigargin were used as positive control (C+).
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apoptosis were decreased by 4-PBAwhen autophagy was impaired,
finally corroborating the primary chaperone function of the drug in
rescuing cell homeostasis (Fig. 7B,C).
To evaluate whether other chemical chaperones could have a
similar effect on OI cells, tauroursodeoxycholic acid (TUDCA),
approved for cholestasis (Wagner and Trauner, 2016), was used.
TUDCA did not show any effect on p-PERK, apoptosis and
autophagy levels, thus suggesting a specificity of 4-PBA in the
rescue of recessive OI fibroblasts homeostasis (Fig. S3).
DISCUSSION
In the past 10 years, the prolyl-3-hydroxylation complex has been
demonstrated to be crucial for proper type I collagen folding and
post-translational modifications (Marini and Blissett, 2013).
Mutations in any of its components, CRTAP, P3H1 and CyPB,
are associated with recessive forms of moderate to lethal OI,
characterized by the presence of abnormal ECM and impaired
mineralization associated with bone fragility (Marini et al., 2017).
Here, we move our attention from the extra- to the intracellular space
and describe the effect of overmodified type I collagen on cellular
homeostasis of seven recessive OI cases, three carrying mutations in
CRTAP, three in P3H1 and one in PPIB, using skin fibroblasts in
which no mutant protein was detectable (Fig. 1C).
Overmodified type I collagen in recessive OImutants causes
UPR and apoptosis activation
In all cell lines, the presence of overmodified collagen was
demonstrated by metabolic labeling and electrophoretic analysis
Fig. 4. Recessive OI cells react to
cellular stress by activating autophagy.
(A) Representative western blot (left) and dot
plot of the quantitative analysis (right) of the
terminal autophagic marker LC3 in control
(WT) and in cells with mutations in CRTAP,
P3H1 or CyPB. LC3-II is upregulated in all
cases except in patient P3H1-2. β-actin was
used for normalization. (B) Representative LC3
western blot (left) performed on cell lysates
obtained following chloroquine incubation from
WT and mutant samples, and dot plot of the
quantitative analysis (right). The terminal
marker of autophagy evaluated in dynamic
conditions is increased in CRTAP-2, CRTAP-3,
P3H1-2 and CyPB. β-actin was used for
normalization. (C) Representative LC3
immunofluorescence images of WT and
mutant fibroblasts treated with chloroquine.
Quantitation of the total area of punctate signal
per cell confirms the activation of autophagy.
DAPI (nuclei) in blue and LC3 in green.
Magnification 40×, zoom 4×. WT values are
represented as black dots; CRTAP as gray
dots; P3H1 as white dots; CyPB as dark gray
dots. *P<0.05. Scale bar: 40 µm.
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(Fig. 2A). Likely due to the increased accumulation of type I
collagen molecules in the ER, cisternae enlargement and cellular
vacuolization were detected (Fig. 5B). Interestingly, in the presence
of similar broadening of the α-bands, significant intracellular
collagen retention and ER enlargement was not clearly evident in
P3H1-2 cells, suggesting a variable ability of the cells to handle
Fig. 5. See next page for legend.
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overmodified type I collagen, either due to a different level of
collagen overmodification or to the effect of modifiers affecting
collagen secretion (Fig. 2, Fig. 5B). Indeed, although collagen
electrophoretic analysis is a quick and simple tool to reveal post-
translational overmodifications, it does not allow the detection of
subtle differences (Barnes et al., 2006; Cabral et al., 2007) that have
been previously demonstrated in OI patients and may potentially
impact on protein secretion (Amor et al., 2011; Barnes et al., 2006;
Marini et al., 2007; Taga et al., 2013). Furthermore, the functional
role of collagen O-glycosylation is not clearly defined yet and,
if some information is available regarding its possible extracellular
effect on increasing collagen stability against proteolytic
degradation, control of lateral growth of the fibrils, interaction
with non-collagenous proteins and the cross-linking process,
nothing has been reported so far on its intracellular effect
(Perdivara et al., 2013).
Following collagen folding in the ER, its secretion requires the
assembly of specific large COPII vesicles, whose formation
depends on a large number of proteins and lipids. Thus, it is not
surprising that the complex collagen secretory machinery may be
tuned by the action of modifiers (Vollmann et al., 2017).
To maintain the functional integrity of ER under stress
conditions, the evolutionarily conserved adaptive response, the
UPR, is generally turned on. Indeed, UPR activation affecting cell
homeostasis and likely modulating disease severity was reported
in the presence of mutations in ECM molecules, including the
fibrillar collagen type II and X (Boot-Handford and Briggs, 2010).
In recessive OI cells, the PERK branch of the UPR is activated,
as demonstrated by an increased p-PERK:PERK ratio and
upregulation of its effector ATF4 (Fig. 3C). In the presence of ER
stress, BIP, the master regulator of activation of the UPR branches, is
released from the UPR sensors to favor protein folding and this
event activates the specific ER cellular response. Interestingly, three
out of seven OI cell lines did not show upregulation of BIP, hinting
at other regulatory proteins being involved in the ER stress response
in the presence of overmodified type I collagen retention, as
suggested in previous reports (Besio et al., 2018; Forlino et al.,
2007; Mirigian et al., 2016). UPR activation is not sufficient for cell
homeostasis and CRTAP-2, CRTAP-3, P3H1-2 and CyPB recessive
OI fibroblasts also showed upregulated autophagy (Fig. 4), which is
often activated to regulate the lysosome-dependent turnover of cell
materials to reduce the ER overload (Galluzzi et al., 2017; Green
and Levine, 2014). Surprisingly, autophagy was also stimulated in
P3H1-2 cells in which no reduction of collagen secretion, no UPR
activation and no ER cisternae enlargement were detectable. The
splice-site mutation in this cell line (c.1223+2T>G), predicted to
cause exon 7 removal, should result in the translation of a shorter
P3H1 (p.Asp391Valfs46) that could indeed be eliminated through
Fig. 5. 4-PBA ameliorates recessive OI fibroblast homeostasis.
(A) Representative western blots (top) and dot plot of the quantitative
analysis (bottom) of p-PERK and cleaved caspase 3 (CASP3) in the absence
(−) or presence (+) of 4-PBA incubation in control (WT) cells and in cells
with mutations in CRTAP, P3H1 or CyPB. The levels of these proteins were
compared in treated versus untreated cells and in treated OI cells versus
untreated controls. β-actin was used for normalization. *P<0.05 mutant
fibroblasts with respect to control fibroblasts. #P<0.05 treated mutant
fibroblasts with respect to untreated mutant fibroblasts. §P<0.05 treated
mutant fibroblasts with respect to untreated control fibroblasts. p-PERK:PERK
and cleaved caspase 3 levels were decreased to or even less than control
values in all cases, with the exception of P3H1-2. WT untreated values are
shown as black dots, mutants untreated as white dots and mutants treated
as gray dots. (B) Transmission electron microscopy representative images
of OI patient fibroblasts in the absence (−) or presence (+) of 4-PBA. The
analyses revealed ER enlargement (*) and cellular vacuolization (arrow) in
mutant cells with the exception of P3H1-2. 4-PBA treatment reduced the
ER cisternae enlargement. Magnification 20,000×. (C) Representative western
blot of CRTAP and P3H1 in control (WT) and CRTAP-3 cell lysates, and of
CyPB in WT and CyPB lysates. No protein rescue was detected after the
treatment in the two mutant cell lines, in which normal transcript level was
detected. β-actin was used for normalization. Scale bar: 2 µm.
Fig. 6. 4-PBA stimulates protein secretion and autophagy. (A) Dot plot representing the amount of general protein secreted in the absence or presence of
4-PBA treatment in WT and OI patient fibroblasts. In the samples in which protein secretion was impaired in the basal condition, it was rescued by 4-PBA treatment.
(B) Representative western blot to evaluate LC3 expression (top) in control (WT) and patient cells in the absence (−) and presence (+) of 4-PBA, and dot plot of
the quantitative analysis (bottom). An increase of LC3-II levels in cells after 4-PBA treatment was detected. *P<0.05 mutant fibroblasts with respect to control
fibroblasts. #P<0.05 treated mutant fibroblasts with respect to untreated mutant fibroblasts. §P<0.05 treated mutant fibroblasts with respect to untreated control
fibroblasts. β-actin was used for normalization. WT untreated values are shown as black dots, mutants untreated as white dots and mutants treated as gray dots.
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Fig. 7. 4-PBA chaperone function is mainly responsible for homeostasis rescue in the recessive OI cells. (A) ER proteostasis was evaluated
using thioflavin T (ThT). Representative immunofluorescence images are shown on the left and the fluorescence quantitation graph is reported on the right.
Mutant cells revealed an increased fluorescence compared to control, indicating the intracellular accumulation of misfolded proteins. 4-PBA treatment significantly
reduced the ThT fluorescence, proving its chaperone role also following autophagy inhibition with chloroquine. WT is shown in black, mutants in gray.
(B) Representativewestern blot to evaluate pPERK:PERK expression in the absence (−) and presence (+) of 4-PBA and of chloroquine and quantitative analysis.
4-PBA normalized the p-PERK:PERK ratio even when autophagy was impaired. β-actin was used for normalization. WT untreated values are shown as
black dots, mutants untreated as gray dots, cells treated with chloroquine as white dots. (C) Representative FACS plots and quantitative analysis of the fraction
of apoptotic events following staining with annexin V (FITC) and propidium iodide (PI) in the absence (−) and presence (+) of chloroquine and of 4-PBA. Even
when autophagy was impaired, 4-PBA decreased apoptosis. *P<0.05 mutant fibroblasts treated with chloroquine with respect to untreated. #P<0.05 mutant
fibroblasts treated with 4-PBA and chloroquine with respect to treated with chloroquine. §P<0.05 mutant fibroblasts treated with 4-PBA and chloroquine with
respect to untreated fibroblasts. Scale bar: 20 µm.
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autophagy. Nevertheless, the strong reduction of RNA expression
demonstrated the activation of nonsense-mediated decay, likely
minimizing the amount of protein synthesis. Despite autophagy
activation, apoptosis was promoted in all analyzed cell lines
(Fig. 3A).
Common pathways are activated in recessive and classical
forms of OI
The reported overmodified collagen retention, UPR activation and
cell death found in recessive OI type VII, VIII and IX resemble what
was previously detected in the OI forms due to mutations in
COL1A1 and COL1A2 genes and characterized by the synthesis of
structurally altered collagen molecules. In particular, in fibroblasts
from patients with classical OI forms, we recently demonstrated
that the intracellular-retained overglycosylated collagen causes ER
cisternae enlargement, and the inefficiency of the UPR to counteract
the constitutive synthesis of mutant collagen brought cells to death
(Besio et al., 2018). In our system, we also described autophagy
activation as a general mechanism associated with COL1A1
mutations, but detectable only in few cases with mutations in
COL1A2 (Besio et al., 2018). We hypothesized that endogenous
autophagy in OI cells could be linked to the presence of a higher
amount of mutant collagen since, due to its stoichiometry, 75% of
trimers will be overmodified in the presence of mutant α1, versus
50% when α2 chains are mutated. Interestingly, in the analyzed
recessive cells, in which all the collagen type I is overmodified, not
all patients had the same autophagic response. Although we cannot
exclude a mutation or site-dependent effect of structural defects in
collagen chains, these new results support the hypothesis of a role
for modifiers in modulating cell response to stress. Indeed, in a
previous study using skin and bone samples from the Brtl mouse, a
model for dominant OI carrying a G349C substitution in α1(I) and
either a moderate or a lethal outcome, we found in mice with non-
lethal outcome a better ability to react to mutant collagen retention.
Such capacity was associated with an increased expression of
chaperone proteins (Bianchi et al., 2012; Forlino et al., 2007). Some
years later, we confirmed a different ability to manage cell stress and
thus to guarantee cell homeostasis in patients cells carrying identical
mutation, but different outcome (Besio et al., 2018).
Of note, independently from the autophagic cellular response,
apoptosis is upregulated in both dominant and recessive mutant
cells. Thus, apoptotic pathway activation represents a hallmark of
unsolved cell stress, both in dominant and in recessive forms of the
disease (Besio et al., 2018; Bianchi et al., 2012; Galluzzi et al.,
2017; Green and Levine, 2014; Mirigian et al., 2016). P3H1-2
represents an exception to this rule since, in this cell line, apoptosis
is not activated by sustained ER stress due to mutant collagen
retention, but possibly as a consequence of sustained autophagy.
4-PBA: a potential common therapy for recessive and
classical forms of OI
The identification of novel targets for disease treatment is of
valuable significance to develop novel therapies. The recognition of
altered pathways common to several diseases is even more relevant
for rare diseases with a limited number of affected patients. We
previously proved that 4-PBA successfully ameliorates classical OI
cell homeostasis in vitro using OI patients’ fibroblasts, and bone
phenotype in vivo using the OI zebrafish model Chihuahua (Besio
et al., 2018; Gioia et al., 2017). The drug activated autophagy and
increased general protein secretion in OI dominant fibroblasts,
and improved bone mineralization and bone histomorphometric
parameters in the zebrafish model. 4-PBA is an FDA-approved drug
for urea cycle disorders; thus, its repositioning for a different disease
will definitely speed up the bench-to-bedside transition (Matoori
and Leroux, 2015). Nevertheless, the multiple recognized functions
of 4-PBA need to be taken into consideration for a proper data
interpretation. Associated to its ammonia scavenger role, 4-PBA has
a recognized chaperone function, favoring ER protein folding and
thus attenuating the UPR in the presence of ER stress caused by
misfolded protein accumulation (Pettit and Fellner, 2014), and
it acts as a histone deacetylase inhibitor, modulating chromatin
accessibility and thus gene expression (Butchbach et al., 2016).
Interestingly, at least in yeast cells, 4-PBA attenuates the UPR by
accelerating the degradation of the ER-stress sensor Ire1, rather than
by restoring the global protein folding; indeed, UPR attenuation was
detectable even in the absence of ER stress (Daosukho et al., 2007;
Mai et al., 2018).
Here, we dissected whether the positive effect of 4-PBAwas due
to its autophagy-stimulating ability or to its chaperone function, and
finally proved its relevance in assisting protein secretion.
Taking all these findings into consideration, our results prove and
extend the potential use of 4-PBA as chemical chaperone to the OI
forms characterized by overmodified collagen production. For
the first time, we demonstrated the potential pharmacological
benefit of this drug for the recessive forms of OI with defects in the
3-hydroxylation complex. In almost all the analyzed fibroblasts
carrying mutations in the P3H1 complex, 4-PBA administration
reduced PERK activation and decreased apoptosis (Fig. 5A). The
improved general protein secretion detected in the recessive OI
resembles the findings described in dominant cases. The restoration
of normal ER cisternae size (Fig. 5B) and the reduced ThT
fluorescence (Fig. 7A) further supports the reduction of misfolded
protein accumulation.
Of note, treatment of CyPBmutant cells seems to act in a different
way. Drug administration reduced apoptotic death, but neither
autophagy nor protein secretion were significantly augmented.
CyPB is involved in other intracellular complexes. It is a binding
partner for lysyl hydroxylase isoforms, thus affecting collagen
hydroxylation and crosslinks, and interacts with BIP and PDI, thus
having a relevant role in the folding of the collagen C-propeptides
and on the kinetics of collagen chain association (Gruenwald et al.,
2014; Heard et al., 2016; Terajima et al., 2016). Indeed, PPIB-null
cells showed a delay in trimer association together with the
increased post-translational modification present also in CRTAP-
and P3H1-null cells (Pyott et al., 2011; van Dijk et al., 2009). With
the limit of the use of a single cell line, mainly due to the extreme
rarity of OI type IX, we can hypothesize that the multiple roles of
CyPB may be differentially and specifically affected/modulated by
4-PBA treatment, and further experiments will be necessary to shed
light on the mechanism.
Study limitations
As a cellular model, we used primary fibroblasts from recessive OI
patients. Since skin biopsy has limited invasiveness, a large body of
literature is available on OI biochemical characterization based on
this cell type, and fibroblasts share with osteoblasts the production
of a high amount of collagen type I and several biochemical
pathways (Bianchi et al., 2012). Furthermore, a skin phenotype is
often described in OI patients (Balasubramanian et al., 2016).
Nevertheless, OI is mainly a bone disorder and the bone-forming
cells are known to produce even higher amounts of collagen type I,
with a higher glycosylation level compared to fibroblasts (Sarafova
et al., 1998). Indeed, how osteoblasts react to mutant collagen
retention has been recently addressed using calvarial osteoblasts
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from the OI knock-in murine model α2(I)-G610C. The misfolded
procollagen was found accumulated in the ER, causing an unusual
cell stress, which was neither activating a conventional UPR nor
causing ER overload, although EIF2α was found phosphorylated
(Mirigian et al., 2016). Interestingly, in a more recent paper using
the same OI murine model, ER-stress-related genes were found
upregulated in hypertrophic chondrocytes expressing type I
collagen (Scheiber et al., 2019). Further investigation in different
murine models and, likely, in human osteoblasts are necessary.
For proper interpretation of our results, it should also be
considered that the in vitro growth and expansion of the cells
could have imposed an artificial ‘stress’ that we cannot exclude to
have some effects on the activation of specific UPR branches.
Anyway, all controls and mutant cell lines were similarly expanded,
likely supporting the truthfulness of the described differences. To
properly translate in vitro data to patients, in vivo validation is
needed. We recently demonstrated in osteoblasts from the OI
zebrafish model Chihuahua an ER cisternae enlargement associated
with mutant collagen type I synthesis and we proved that 4-PBAwas
indeed restoring ER cisternae size, likely favoring collagen
secretion (Gioia et al., 2017). The identification of the involved
pathways in mammals needs further investigation.
In conclusion, we identified ER stress as a common potential
target for the treatment of recessive OI carrying mutations in
components necessary for collagen post-translational modifications
and for the cure of classical dominant OI. The finding that the same
chemical chaperone is effective in cells synthesizing overmodified
collagen increases the potential clinical use of 4-PBA for multiple
OI forms.
MATERIALS AND METHODS
Human fibroblasts
Seven human primary dermal fibroblasts from skin biopsies of OI patients
carrying mutations in one of the genes coding for the three members of the
collagen prolyl 3-hydroxylation complex – CRTAP (CRTAP-1, CRTAP-2,
CRTAP-3) (Amor et al., 2011; Caparros-Martin et al., 2013; Valli et al.,
2012), P3H1 (P3H1-1, P3H1-2 and P3H1-3) (Caparros-Martin et al., 2013)
and PPIB (CyPB) (Caparros-Martin et al., 2013) – and three pediatric
controls (Promo Cell) were obtained after informed consent and used up to
passage 10 (P10) (Table 1). Cells were grown at 37°C in humidified
atmosphere containing 5% CO2 and cultured in Dulbecco’s modified
Eagle’s medium (DMEM; 4.5 g/l glucose; Lonza) supplemented with 10%
fetal bovine serum (FBS; Euroclone), 4 mM glutamine (Euroclone), 100 μg/
ml penicillin and streptomycin (Euroclone). No ascorbic acid was added to
expansion media. For each experiment, except where differently stated,
2.5×104 cells/cm² were plated and harvested after 5 days with no media
change. For drug treatment, cells were incubated for 15 h with 5 mM 4-PBA
(Sigma-Aldrich) or with 0.96 mM TUDCA (Sigma-Aldrich). The lysosome
fusion with autophagosome was blocked using 10 μM chloroquine (Sigma-
Aldrich) for 6 h.
Sequencing
Genomic DNA from P3H1-1 was extracted from fibroblasts by standard
procedure. Exons were amplified by PCR and Sangers’ sequencing was
performed.
Expression analysis
Total RNA was extracted from patients’ fibroblasts using TriReagent
(Sigma-Aldrich) according to the manufacturer’s protocol. DNase digestion
was performed using the Turbo DNA Free Kit (Ambion, Applied
Biosystems), and RNA integrity was verified on agarose gel. cDNA was
synthetized and qPCR was performed on the Mx3000P Stratagene
thermocycler using Syber Green Master Mix (Applied Biosystems)
with custom primers. For CRTAP (NM_006371.4) the forward primer
was 5′-CCCAGACCTGAAGCAGTT-3 (nt 1180-1197) and the reverse
primer was 5′-TTCTCCCTCATCATCATCCATT-3′ (nt 1278-1257). The
PPIB (NM_000942 .4) forward primer was 5′-GGAGAGAAAGGATT-
TGGCTAC-3′ (nt 413-433) and the reverse primer was 5′-CAGGCTGTC-
TTGACTGTCGTGA-3′ (nt 651-630). The P3H1 (NM_001243246.1)
forward primer was 5′-CGGGTGGCTGGCGGTTCCG-3′ (nt 78-96)
and the reverse primer was 5′-ACCTCGGCTTGGGAGGCAGC-3′ (nt
184-165). All reactions were performed in triplicate. GAPDH was used as
normalizer. The GAPDH (NM_002046.5) forward primer was 5′-ATAC-
CAGGAAATGAGCTTGACAAA-3′ (nt 1035-1057) and the GAPDH
reverse primer was 5′-TCCTCTGACTTCAACAGCGACAC-3′ (nt 1130-
1107). Relative expression levels were calculated using the ΔΔCt method.
Protein lysates
Fibroblasts werewashed and scraped in PBS, centrifuged at 1000 g for 4 min,
lysed and sonicated in RIPA buffer (150 mM NaCl, 1% IGEPAL® CA-630,
0.5% sodiumdeoxycholate, 0.1%SDS, and 50 mMTris, pH 8) supplemented
with protease inhibitors (13 mM benzamidine, 2 mM N-ethylmalemide,
5 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride
and 2 mM NaVO3). Proteins were quantified by RC DC Protein Assay (Bio-
Rad). Bovine serum albumin (BSA) (Sigma-Aldrich) was used as standard.
Western blot
Proteins from human fibroblast lysates (10-50 μg) were separated on
SDS-PAGE with acrylamide percentage ranging from 6 to 15%, depending
on the size of the analyzed protein (Table S1). The proteins were
electrotransferred to a PVDF membrane (GE Healthcare) at 100 V for 2 h
on ice in 19 mM Tris-HCl, 192 mM glycine and 20% (v/v) methanol. The
membranes were then blocked with 5% (w/v) BSA in 20 mM Tris-HCl,
500 mM NaCl, pH 7.5 (TBS), 0.05% (v/v) Tween-20 (Sigma-Aldrich)
(TBS-T) at room temperature (RT) for 1 h. After washing with TBS-T, the
membranes were incubated with 1:1000 primary antibody against the
specific proteins CRTAP (generously provided by Dr Lee Brendan, Baylor
College of Medicine,TX, USA), P3H1 (NovusBio), CyPB (Proteintech),
BIP (Cell Signaling), PERK (Cell Signaling), PDI (Cell Signaling), p-PERK
(Thr980; Cell Signaling), LC3A/B (Cell Signaling), cleaved caspase-3 (Cell
Signaling), ATF4 (Novus Biological), ATF6 (Abcam) in 5%BSA in TBS-T
overnight at 4°C. The appropriate secondary antibody anti-mouse (Cell
Signaling), anti-rabbit (Cell Signaling) or anti-goat (Santa Cruz
Biotechnology) was added at dilution of 1:2000 in 5% BSA in TBS-T for
1 h at RT. Anti-β-actin antibody (Santa Cruz Biotechnology) diluted 1:1000
in 5% BSA in TBS-T was used for protein loading normalization. The signal
was detected by ECLwestern blotting detection reagents (GEHealthcare) and
imageswere acquiredwith ImageQuant LAS 4000 (GEHealthcare), using the
ImageQuant LAS 4000 1.2 software. Band intensities were evaluated by
densitometry, using ImageQuant TL analysis software. For each gel, the
intensity of the control band was set equal to one, and the expression of the
mutant samples was expressed as fold difference. For each cell line, three
independent lysates were collected and technical triplicates were performed.
Collagen analysis
Labeling of collagen with L-[2,3,4,5-3H]-proline (PerkinElmer) was used to
evaluate collagen overmodification and secretion. A total of 2.5×104
fibroblasts/cm2 were plated into 6-well plates and grown for 24 h. Cells
were then incubated for 2 h with serum-free DMEM containing 4 mM
glutamine, 100 μg/ml penicillin and streptomycin, and 100 μg/ml (+)-sodium
L-ascorbate (Sigma-Aldrich) to stimulate collagen production. For
steady-state experiments, the labeling was performed for 18 h in the same
media using 28.57 μCi of 3H-Pro/ml. For chase experiments, the labeling was
performed for 4 h using 47.14 μCi of 3H-Pro/ml, then the labeling media was
replaced with serum-free DMEM containing 2 mM proline (Sigma-Aldrich),
4 mM glutamine, 100 μg/ml penicillin and streptomycin, and 100 μg/ml
(+)-sodiumL-ascorbate (chasemedia). Collagen was collected at 0.5, 1, 2 and
3 h after the chase. Collagen extraction was performed as previously reported
(Forlino et al., 2019; Valli et al., 1991). Briefly, medium and cell lysate
fractions were digested overnight with 100 ng/ml of pepsin in 0.5 M acetic
acid at 4°C. Collagen was then precipitated using 2 M NaCl, 0.5 M acetic
acid. Collagen was resuspended in Laemmli buffer (62 mMTris-HCl, pH 6.8,
10% glycerol, 2% sodium dodecyl sulfate, 0.02% Bromophenol Blue) and
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the radioactivity [counts per minute (CPM)] was measured using a liquid
scintillation analyzer (PerkinElmer TRI-CARB 2300 TR).
For steady-state analyses, equal amounts of 3H-labeled collagen from
each patient’s cells were loaded on 6% urea-SDS gels in a non-reducing
condition. For chase analyses, the same volume of 3H-labeled collagens
from each time point was electrophoresed. The gels were fixed in 45%
methanol, 9% glacial acetic acid, incubated for 1 h with enhancer
(PerkinElmer, 6NE9701), washed in deionized water and dried. 3H gel
radiographs were obtained by direct exposure of dried gels to hyperfilm
(Amersham) at−80°C. The radiography films were digitalized by VersaDoc
3000 (Bio-Rad). To quantify the intracellular collagen retention, the ratio
between the CPM in the cell layer and the CPM in medium plus cell layer
was evaluated. To quantify the percentage of collagen secretion, the ratio
between the density of the α1(I) band in the media and the total collagen
(medium plus cell layer) was evaluated by Quantity One software (Bio-Rad)
(Ciccocioppo et al., 2013).
To analyze the effect of 4-PBA on collagen secretion, cells were labeled
for 18 h in the absence or presence of 5 mM 4-PBA using 28.57 μCi of
3H-Pro/ml. Collagen extraction from the media was performed as previously
reported and an equal volumewas loaded on the SDS-urea-PAGE. The ratio
between the density of the α1(I) band in the medium was evaluated on the
digitalized fluorography, and the value was normalized to the DNA
extracted from the cell layer.
Transmission electron microscopy analysis
For transmission electron microscopy analysis, fibroblasts from controls and
patients were trypsinized and centrifuged at 1000 g for 3 min. The pellet was
fixed with 1% glutaraldehyde in the culture medium for 2 h at RT. The cells
were rinsed in PBS and then in H2O. Finally, the fibroblasts were fixed in
2% (w/v) OsO4 in H2O for 2 h at RT, rinsed in distilled water and embedded
in 2% agarose. The specimens were dehydrated in acetone and finally
infiltrated with epoxy resin overnight and polymerized in gelatin capsules at
60°C for 24 h. Thin sections (60-70 nm thick) were cut on a Reichert OM-
U3 ultramicrotome with a diamond knife and collected on 300-mesh nickel
grids. The grids were stained with saturated aqueous uranyl acetate by lead
citrate and observed with a Zeiss EM900 electron microscope, operated at
80 kV with objective aperture of 30 μm.
XBP1 splicing analyses
cDNA from control and patients cells was used for PCR amplification
across the region of the XBP1 cDNA (NM_005080.3) containing the
intronic target of IRE1α ribonuclease using 0.3 μM sense (nt 396-425;
5′-TCAGCTTTTACGAGAGAAAACTCATGGCCT-3′) and antisense (nt
696-667; 5′-AGAACATGACTGGGTCCAAGTTGTCCAGAA-3′) primers.
Following a 30 min incubation at 50°C, reactions were cycled 30 times at
94°C, 60°C and 72°C for 30 s at each temperature. Reaction products were
electrophoresed on 8% TBE acrylamide gels and visualized by ethidium
bromide staining.
LC3 immunofluorescence
A total of 1.5×104 fibroblasts were plated on sterile glass coverslips
(Marienfeld) in 24-well plates in triplicate. After 5 days, cells were treated
for 6 h with 10 μM chloroquine. Following the treatment, the medium was
removed and cells were fixed with cold 100% CH₃OH for 15 min at −20°C,
washed three times with PBS and blocked for 1 h in 1% BSA in PBS
containing 0.3% Triton X-100. Then, cells were incubated with LC3
primary antibody (Cell Signaling) diluted 1:500 in 1% BSA, 0.3% Triton
X-100 in PBS overnight at 4°C. Cells werewashed three times with PBS and
incubated with secondary antibody [Alexa-Fluor-488-conjugated F(ab′)
fragment anti-rabbit IgG, Immunological Sciences] diluted 1:2000 in 1%
BSA, 0.3% Triton X-100 in PBS for 2 h at RT. Nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). The samples were
analyzed using an SP5-Leica confocal microscope (Leica). The total area of
punctate signal per cell was measured by the Leica software LAS4.5.
Thioflavin-T labeling
A total of 1.5×104 fibroblasts were plated on sterile glass coverslips
(Marienfeld) in 24-well plates. After 4 days, cells were incubated with 5 μM
Thioflavin T (ThT; Sigma-Aldrich) for 15 h in the presence or absence of
4-PBA and in the presence or absence of chloroquine. The medium was
removed and cells were fixed with 4% paraformaldehyde in PBS for 20 min
at RT. Nuclei were stained with DAPI (Sigma-Aldrich). The samples were
analyzed using an SP8-Leica confocal microscope (Leica). The excitation
and emission settings were: DAPI (Ex. MP laser 800 nm, Em. 410-530 nm),
ThT (Ex. 458 nm, Em. 480-520 nm). The total area of punctate signal per
cell was measured using the Leica software LAS4.5.
Fluorescence activated cell sorting (FACS)
To analyze apoptosis, the FACS Annexin V/Dead Cell Apoptosis Kit
(Invitrogen) was used following the manufacturer’s instructions. As positive
control for the activation of apoptosis, cells were treated with 20 μM
thapsigargin (Sigma-Aldrich) for 24 h in serum-free DMEM. Samples were
analyzed by Cell Sorter S3 (Bio-Rad); 1×104 events for each sample were
considered measuring the fluorescence emission at 510-540 nm and
>565 nm. For autophagy inhibition, 50 μM chloroquine was used.
Protein secretion
OI patients’ fibroblasts were plated in 24-well plates and labeled with 5 μCi/
ml [35S] EXPRESS35S Protein Labeling Mix (PerkinElmer) in DMEM
without L-methionine, L-cystine and L-glutamine for 1 h at 37°C. Total
proteins from medium and cell layer were precipitated with 10%
trichloroacetic acid. Proteins were washed with acetone twice and
resuspended in 60 mM Tris-HCl, pH 6.8, 10% sodium dodecyl sulphate.
The radioactivity (CPM) of the samples was measured using a liquid
scintillation analyzer (TRI-CARB 2300 TR). The percentage of protein
secretion was calculated based on the ratio between the CPM in the media and
the CPM in medium and cell layer, evaluated in five technical replicates.
Statistical analysis
Statistical differences between patients and controls were evaluated by
two-tailed Student’s t-test. Statistical differences between controls, patients
and treated patients and between the different treatments were evaluated by
one-way ANOVA using Sigma plot 11.0 (Fisher). All data passed tests for
normality and equal variance. Technical triplicates were performed and values
were expressed as mean±s.d. A P-value <0.05 was considered significant.
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Ishikawa, Y. and Bächinger, H. P. (2013). A molecular ensemble in the rER for
procollagen maturation. Biochim. Biophys. Acta 1833, 2479-2491. doi:10.1016/j.
bbamcr.2013.04.008
Ishikawa, Y., Wirz, J., Vranka, J. A., Nagata, K. and Bächinger, H. P. (2009).
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